OFATUMUMAB for Relapsing-remitting multiple sclerosis: Side Effects & Safety Data
Boost Your Natural Energy & Metabolism
Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.
There are 3,864 adverse event reports in the FDA FAERS database where OFATUMUMAB was used for Relapsing-remitting multiple sclerosis.
Most Reported Side Effects for OFATUMUMAB
| Side Effect | Reports | % | Deaths | Hosp. |
|---|---|---|---|---|
| Fatigue | 5,202 | 17.4% | 8 | 361 |
| Headache | 4,430 | 14.8% | 6 | 300 |
| Pain | 3,382 | 11.3% | 2 | 243 |
| Chills | 3,372 | 11.3% | 2 | 176 |
| Pyrexia | 3,370 | 11.3% | 31 | 436 |
| Influenza like illness | 2,727 | 9.1% | 2 | 149 |
| Nausea | 1,688 | 5.6% | 6 | 160 |
| Multiple sclerosis relapse | 1,525 | 5.1% | 2 | 361 |
| Covid-19 | 1,435 | 4.8% | 12 | 254 |
| Asthenia | 1,393 | 4.7% | 9 | 198 |
| Gait disturbance | 1,342 | 4.5% | 2 | 201 |
| Hypoaesthesia | 1,316 | 4.4% | 0 | 167 |
| Feeling abnormal | 1,306 | 4.4% | 2 | 112 |
| Multiple sclerosis | 1,267 | 4.2% | 6 | 131 |
| Malaise | 1,243 | 4.2% | 10 | 171 |
Other Indications for OFATUMUMAB
Multiple sclerosis (11,816)
Product used for unknown indication (9,779)
Relapsing multiple sclerosis (3,705)
Chronic lymphocytic leukaemia (1,216)
Secondary progressive multiple sclerosis (1,099)
Clinically isolated syndrome (1,075)
Multiple sclerosis relapse (158)
Mantle cell lymphoma (143)
Marginal zone lymphoma (131)
Central nervous system lymphoma (128)
Other Drugs Used for Relapsing-remitting multiple sclerosis
OCRELIZUMAB (15,658)
FINGOLIMOD (8,814)
DIMETHYL (3,638)
NATALIZUMAB (2,749)
INTERFERON BETA-1A (2,058)
GLATIRAMER (1,965)
ALEMTUZUMAB (1,604)
TERIFLUNOMIDE (1,320)
RITUXIMAB (956)
TECFIDERA (806)